Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Uro-genital condition treatment system

A single, dimer technology for therapeutic applications in genitourinary disorders

Inactive Publication Date: 2004-11-10
ZENGEN
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although effective, some strains of S. aureus have become resistant and only a few antibiotics are effective against methicillin-resistant S. aureus (MRSA)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Uro-genital condition treatment system
  • Uro-genital condition treatment system
  • Uro-genital condition treatment system

Examples

Experimental program
Comparison scheme
Effect test

Embodiment I

[0042] The purpose of this example is to elucidate the antimicrobial properties of α-MSH and / or its derivatives, where Staphylococcus aureus is taken as an example.

[0043] Staphylococcus aureus cultures (ATCC 29213) were provided by the Department of Microbiology, Ospedale Maggiore di Milano. Staphylococcus aureus (1×10 in Hank’s balanced salt solution 6 / ml) in the presence or absence of α-MSH(1-13) (sequence number 4), α-MSH(11-13) (sequence number 1) or KPV dimer, cultured at 37°C for 2 hours, the peptide concentration was 10 -15 -10 -4 M. Cells were then rinsed in cold distilled water and diluted to 100 organisms / ml with HBSS. Aliquots of - microliters were spread on plasma agar plates and incubated at 37°C for 24 hours. Microbial viability was then assessed based on the colonies formed. In another experiment, the bacterial concentration was 10 5 Add different peptides and 500 units of urokinase (a growth promoter for Staphylococcus aureus) per 100 ml of culture s...

Embodiment II

[0046] The purpose of this example is to clarify the antifungal properties of α-MSH and / or its derivatives, and the experimental strain selected here is Candida albicans.

[0047] Clinical isolates of C. albicans were provided by the Department of Microbiology, Ospedale Maggiore di Milano. Candida albicans was cultured on a Sabouraud agar slant plate, and periodically transferred to a Sabouraud agar plate, and cultured at 28°C for 48 hours. To prepare stationary yeast, colonies were picked from the agar plate, transferred to 30 ml sabouraud dextrose liquid medium, and cultured at 32°C for 72 hours. The resulting cells were centrifuged at 1000 xg for 10 minutes, and the pelleted cells were washed twice with distilled water. Then count the number of cells and suspend in Hank's Balanced Salt Solution (HBSS) to the desired concentration. Bacterial viability was determined by 0.01% methylene blue efflux test. The results showed that its viability was greater than 98%.

[0048] ...

Embodiment III

[0051] The purpose of this example is to compare the antibacterial activity of α-MSH and / or its derivatives with fluconazole, which is a recognized antifungal drug.

[0052] Detection of α-MSH (1-13) (serial number 4), (4-10) (serial number 2), (6-13) (serial number 3), (11-13) (serial number 1 ) and ACTH(1-39), (18-39) and fluconazole in 10 -6 -10 -4 The anti-Candida albicans ability under M concentration, method is the same as embodiment II. Figure 4 Show that compared with fluconazole, α-MSH (11-13) (sequence number 1), (4-10) (sequence number 2), (6-13) (serial number 3) and (1 -13) (Serial No. 4) is very effective against Candida albicans, and its inhibitory activity is similar to that of fluconazole at an equimolar concentration. In contrast, the core α-MSH sequence (4-10) (SEQ ID NO: 2), which has behavioral effects but little anti-inflammatory activity, produced nearly 50% inhibitory effect on colony-forming units. Although this inhibitory effect is significant (p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is directed to a system for treating uro-genital conditions. One aspect of this invention involves the treatment system comprising one or more polypeptides with an amino acid sequence including KPV (SEQ ID NO: 1), MEHFRWG (SEQ ID NO: 2), HFRWGKPV (SEQ ID NO: 3), SYSMEHFRWGKPV (SEQ ID NO: 4), for treatment of uro-genital conditions. The one or more polypeptides can also be a dimer formed from any of the amino acid sequences above. Uro-genital conditions can include infections, inflammation or both. In one preferred embodiment of the invention, the uro-genital condition includes infection and / or inflammation of the vagina, vulva, urinary tract, penis, and / or the rectum. In another preferred embodiment of the invention, the one or more polypeptides are dissolved in a carrier. In another preferred embodiment of the invention, the one or more polypeptides are associated with a tampon for preventing toxic shock syndrome. In another preferred embodiment, the one or more polypeptides are associated with a contraceptive for prevention of sexually transmitted diseases or infections. In another preferred embodiment, the one or more polypeptides are associated with a suppository for insertion into the vagina or rectum.

Description

[0001] statement [0002] This application is a divisional application of a Chinese patent application filed on March 23, 2000 with the application number 00807953.6 (PCT / US00 / 07846) and the title of the invention being "a therapeutic system for urogenital diseases". This application claims priority to US Provisional Patent Application 60 / 126,233, entitled "Antimicrobial Amino Acid Sequences Derived from Alpha-Melanocyte Stimulating Hormone," filed March 24,1999. technical field [0003] The invention is used for the treatment of urogenital system diseases, especially relates to polypeptide and dimer used for the treatment of urogenital system diseases. Background technique [0004] Genitourinary disorders typically affect both sexes and include infections and / or inflammations of the urinary and reproductive systems. For example, according to the National Institute of Children’s Health and Development (NICHD), “Most women will experience at least one type of vaginitis in th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/02A61F13/20A61K9/00A61K9/06A61K9/107A61K9/12A61K9/20A61K38/00A61K38/07A61K38/34A61P13/00A61P15/00A61P15/18A61P29/00A61P31/04A61P31/10A61P31/12A61P31/18C07K5/09C07K5/103C07K7/06C07K7/08C07K14/575
CPCA61K38/34A61K9/0034A61K38/07A61P13/00A61P15/00A61P15/18A61P29/00A61P31/02A61P31/04A61P31/10A61P31/12A61P31/18
Inventor 詹姆斯·利普顿安娜·卡塔尼亚
Owner ZENGEN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com